The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...

The BioMed X Institute is teaming up with the Barbados government in an effort to accelerate cardiometabolic treatments for ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method ...

On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER), joining the long list of health agency leaders who have departed since ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...